AMNOG Monitor

G-BA Resolutions.
Clearly analysed.

The AMNOG-Monitor provides all relevant information on early benefit assessment and price negotiations, updated daily. A solid foundation for Market Access, HTA, Medical, Business Development, and Pricing.

AMNOG Monitor – Pharmaceutical data analysis
GBA BMG GKV-Spitzenverband KBV AOK Plus Novartis Bayer Boehringer Ingelheim Lilly MSD BioNTech Alnylam Roche Janssen
GBA BMG GKV-Spitzenverband KBV AOK Plus Novartis Bayer Boehringer Ingelheim Lilly MSD BioNTech Alnylam Roche Janssen
GBA BMG GKV-Spitzenverband KBV AOK Plus Novartis Bayer Boehringer Ingelheim Lilly MSD BioNTech Alnylam Roche Janssen
GBA BMG GKV-Spitzenverband KBV AOK Plus Novartis Bayer Boehringer Ingelheim Lilly MSD BioNTech Alnylam Roche Janssen

Features at a glance

Individual decision at a glance

Key data from all AMNOG decisions, summarized in a compact and structured format.

Interactive analysis

Analyze your own research questions by filtering across more than 120 parameters.

Smart search

Fast, quality-assured search of original documents such as dossiers, GBA decisions, justifications (Tragende Gründe), JCAs, and arbitration rulings.

Price trends and annual therapy cost tracking

Price trends for all AMNOG drugs and appropriate comparator therapies (ACTs) at PZN level and for annual therapy costs. Simulate the price negotiation by weighting current ACT costs, including low-cost generics and biosimilars.

EU-HTA

Integration of EU dossiers and JCAs into the AMNOG-Monitor, including PICOs, study results with effect measures, and comparison with AMNOG procedures.

MFN Tracker

All new FDA approvals with their EU, JCA, and AMNOG status. Key figures on FDA and EMA approvals and on the delay of EU approval since the US most-favored-nation (MFN) order.

Current resolutions

Three more EU-HTA procedures started

13. November 2026

Three more EU-HTA procedures started

The European health technology assessment has been started for the following three new oncology active substances:

  • Savolitinib: For the treatment of adult patients with locally advanced or metastatic non-small cell …
Read more →
Fifteen years of AMNOG: evidence base is the strongest driver of added benefit

10. November 2026

Fifteen years of AMNOG: evidence base is the strongest driver of added benefit

At ISPOR Europe 2026 in Vienna (8–11 November 2026), Tomeczkowski et al. presented an analysis of 962 benefit assessment dossiers completed between July 2011 and July 2026. Orphan drugs whose …

Read more →
Location clause under § 130a SGB V

07. November 2026

Location clause under § 130a SGB V

At this year’s “Pharma Trends 2027” conference organised by Forum Institut, Matthias Hiller (CDU), member of the Health Committee of the German Bundestag, discussed the criteria of the planned location …

Read more →